{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:19:35Z","timestamp":1788189575883,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijoms.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijom.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:20:32Z","timestamp":1778271632000},"page":"1141-1146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does previous neck dissection or irradiation mitigate the response to immunotherapy in advanced\/metastatic head and neck squamous cell carcinoma?"],"prefix":"10.1016","volume":"55","author":[{"given":"L.","family":"Kampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Oestreicher-Kedem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gutfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Muhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Warshavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijom.2026.04.018_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/GCO.0000000000000257","article-title":"Targeting the programmed cell death-1 pathway in breast and ovarian cancer","volume":"28","author":"Emens","year":"2016","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"10183","key":"10.1016\/j.ijom.2026.04.018_bib2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 Trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijom.2026.04.018_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, Phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijom.2026.04.018_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","article-title":"Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)","volume":"6","author":"Chae","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ijom.2026.04.018_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2019.104460","article-title":"Immunotherapy for head and neck cancer: recent advances and future directions","volume":"99","author":"Cramer","year":"2019","journal-title":"Oral Oncology"},{"key":"10.1016\/j.ijom.2026.04.018_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijom.2026.04.018_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.humpath.2018.07.012","article-title":"Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma","volume":"82","author":"Zhang","year":"2018","journal-title":"Hum Pathol"},{"issue":"16Suppl","key":"10.1016\/j.ijom.2026.04.018_bib8","article-title":"Spatial relationships and immune subsets in the tumor immune microenvironment of head and neck cancers","volume":"41","author":"Henry","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1016\/j.ijom.2026.04.018_bib9","doi-asserted-by":"crossref","first-page":"S729","DOI":"10.1093\/annonc\/mdy424.045","article-title":"KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"29","author":"Burtness","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijom.2026.04.018_bib10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijom.2026.04.018_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102361","article-title":"Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers","volume":"105","author":"Wong","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijom.2026.04.018_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/fon-2018-0405","article-title":"JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer","volume":"15","author":"Yu","year":"2019","journal-title":"Future Oncol"},{"issue":"10212","key":"10.1016\/j.ijom.2026.04.018_bib13","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijom.2026.04.018_bib14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ijom.2026.04.018_bib15","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized Phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijom.2026.04.018_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, Phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijom.2026.04.018_bib17","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijom.2026.04.018_bib18","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes CDC1-dependent antitumor immunity in HNSCC","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijom.2026.04.018_bib19","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijom.2026.04.018_bib20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJMoa1506007","article-title":"Elective versus therapeutic neck dissection in node-negative oral cancer","volume":"373","author":"D\u2019Cruz","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijom.2026.04.018_bib21","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.18.01921","article-title":"Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline","volume":"37","author":"Koyfman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijom.2026.04.018_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijom.2026.04.018_bib23","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijom.2026.04.018_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijom.2026.04.018_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps6084","article-title":"KEYNOTE-040: a phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer","author":"Cohen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijom.2026.04.018_bib26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ijom.2026.04.018_bib27","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.3390\/ijms22094981","article-title":"Prognostic and predictive factors in advanced head and neck squamous cell carcinoma","volume":"22","author":"Magnes","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijom.2026.04.018_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153934","article-title":"The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma","volume":"236","author":"Wusiman","year":"2022","journal-title":"Pathol Res Pract"}],"container-title":["International Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502726001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502726001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:55:04Z","timestamp":1788188104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0901502726001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0901502726001773"],"URL":"https:\/\/doi.org\/10.1016\/j.ijom.2026.04.018","relation":{},"ISSN":["0901-5027"],"issn-type":[{"value":"0901-5027","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does previous neck dissection or irradiation mitigate the response to immunotherapy in advanced\/metastatic head and neck squamous cell carcinoma?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijom.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Association of Oral and Maxillofacial Surgeons.","name":"copyright","label":"Copyright"}]}}